Innovation in neonatal neurotechnology

CergenX Wave, our FDA breakthrough-designated medical device, leverages advanced AI to identify newborns at highest risk of brain injury.

Innovation in neonatal neurotechnology

CergenX Wave, our FDA breakthrough-designated medical device, leverages advanced AI to identify newborns at highest risk of brain injury.

Innovation in neonatal neurotechnology

CergenX Wave, our FDA breakthrough-designated medical device, leverages advanced AI to identify newborns at highest risk of brain injury.

Innovation in neonatal neurotechnology

CergenX Wave, our FDA breakthrough-designated medical device, leverages advanced AI to identify newborns at highest risk of brain injury.

Healthcare professionals currently struggle to answer this critical question:

Healthcare professionals currently struggle to answer this critical question:

Is this newborn's brain health at risk?

Is this newborn's brain health at risk?

The #2 global cause
of lifelong brain disability is newborn brain injury.¹

>80% of hospitals

can't perform neonatal EEG, the gold standard for newborn neurological assessment.²

50% of cerebral palsy cases

are undetected at birth, leading to challenges that arise from late diagnoses.³

Electroencephalography (EEG) is a direct measure of the electrical activity of the brain.

Patterns in the EEG provide real-time information about brain function and identify babies at risk of brain injury quickly. However, recording a clinical EEG is expensive, time consuming, and requires expert interpretation.⁴ It is generally only available in specialist centres. As a result, many newborns are currently not assessed at birth, missing critical opportunities for early intervention and treatment.

Missed diagnoses can lead to a range of challenges.

These include learning difficulties, physical disabilities, and emotional or behavioural issues that may persist throughout an individual's life. The impact goes beyond the individual, as families often endure emotional stress and financial strain due to long-term care needs.⁵˒⁶ Additionally, healthcare systems face increased demand for specialised services and support.

CergenX aims to change this so that every newborn has timely access to expert brain function assessment.

CergenX aims to change this so that every newborn has timely access to expert brain function assessment.

Introducing:

Introducing:

CergenX Wave

CergenX Wave

FDA

Breakthrough

Device Designation

CergenX Wave is our AI-powered innovation in neonatal neuroprotective care, revolutionising the assessment of newborn brain function.

CergenX Wave is our AI-powered innovation in neonatal neuroprotective care, revolutionising the assessment of newborn brain function.

Results in minutes

Analyses 10 minutes of EEG and provides results without delay.

Objective decision support

Simple & easy to use

Automated AI EEG assessment

For use by all clinicians

Results in minutes

Analyses 10 minutes of EEG and provides results without delay.

Objective decision support

Simple & easy to use

Automated AI EEG assessment

For use by all clinicians

Results in minutes

Analyses 10 minutes of EEG and provides results without delay.

Objective decision support

Simple & easy to use

Automated AI EEG assessment

For use by all clinicians

Our network

References

  1. Steinmetz, Jaimie D et al. Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet Neurology, Volume 23, Issue 4, 344 - 381

  1. Definitive Healthcare reports identifying US healthcare facilities performing newborn EEG, CergenX commissioned, 2024

  1. Novak et al. Early, Accurate Diagnosis and Early Intervention in Cerebral Palsy: Advances in Diagnosis and Treatment.JAMA Pediatr. 2017;171(9):897–907

  1. Sandoval Karamian AG and Wusthoff CJ (2021) Current and Future Uses of Continuous EEG in the NICU. Front. Pediatr. 9:768670. doi: 10.3389/fped.2021.768670

  1. Marlow, N., Shankaran, S., Rogers, E. E., Maitre, N. L., & Smyser, C. D. (2021). Neurological and developmental outcomes following neonatal encephalopathy treated with therapeutic hypothermia. Seminars in Fetal and Neonatal Medicine, 26(4), 101273.

  1. Lemmon ME, Donohue PK, Parkinson C, et al. Parent experience of neonatal encephalopathy: the need for family-centered outcomes. J Perinatol. 2017;37(2):202-206. doi:10.1038/jp.2016.197